Home › Results from HPS2-THRIVE Study of TREDAPTIVE (extended-release niacin/laropiprant) Presented at American College of Cardiology Scientific Sessions
 

Keywords :   


Results from HPS2-THRIVE Study of TREDAPTIVE (extended-release niacin/laropiprant) Presented at American College of Cardiology Scientific Sessions

2013-03-09 18:50:00| Merck.com - Research & Development News

Dateline City:  SAN FRANCISCO SAN FRANCISCO--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers from the Clinical Trial Service Unit at Oxford University presented results from the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study of TREDAPTIVE(extended-release niacin/laropiprant) during a late-breaking clinical trials session at the American College of Cardiology 62nd Annual Scientific Sessions (abstract 300-14). Language:  English Contact HTML:  MerckMedia:Pamela Eisele, 908-423-5042Skip Irvine, 267-305-5397orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: results american study college

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Tropical Storm Beryl Graphics
29.06Tropical Storm Beryl Forecast Discussion Number 2
29.06Tropical Storm Beryl Public Advisory Number 2
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
29.06Tropical Storm Beryl Wind Speed Probabilities Number 2
29.06Tropical Storm Beryl Forecast Advisory Number 2
29.06Atlantic Tropical Weather Outlook
29.06Eastern North Pacific Tropical Weather Outlook
More »